Answers are grounded in this paper and cite their sources.
Biomedical scientists can exploit initiatives from U.S. federal regulatory and funding agencies aimed at accelerating clinical translation.
No takes yet. Share an insight, caveat, or question.
Staff et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: